5 Key Takeaways
-
1
UCSF researchers developed B-SYNC, a preclinical CAR T-cell platform that uses brain-associated brevican to trigger tumor-targeting CAR expression.
-
2
After sensing brevican, B-SYNC cells target either EphA2 or IL-13Rα2, antigens associated with diffuse midline glioma.
-
3
In mouse models, intravenous B-SYNC treatment produced complete tumor regression in 7 of 14 and 4 of 11 animals across two models.
-
4
Ventricular administration eliminated tumors in all 19 treated mice across two models, and surviving animals resisted tumor rechallenge.
-
5
A B7-H3-targeting circuit caused fatal neurotoxicity in mice, while a modified circuit cleared tumors without detectable neurotoxicity; dosing and safety need further study.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
